Latest Views & News

Advanced Oncotherapy - £40m Fundraise, Biggest to Date. So it is a Buy? Er…..

By Nigel Somerville, the Deputy Sheriff of AIM | Thursday 12 August 2021

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

AIM-listed protons beams for cancer outfit Advanced Oncotherapy (AVO) announced a proposed £40 million fundraise yesterday – the largest to date – at 40p per share, a 17% premium to its average closing price over the past month, and a 13% premium to the previous close. I have to hand it to the company, that’s a great effort. But does it make the shares a buy?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was


MADE – Gotcha!

Monday »


Just 26 days to go: Book Now!

Sunday »


Me and “The Millionaire Next Door”

Tuesday »


Synectics – a recovery Buy?



Malcolm Stacey is Moving House

Monday »


Wood Group - a Buy (again)?